Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine

N. J. Vogelzang; R. C. Trowbridge; D. H. Frenning; A. Theologides; B. J. Kennedy; D. R. Kelly; S. L. Ewing; G. J. Vosika

Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine

N. J. Vogelzang, R. C. Trowbridge, D. H. Frenning, A. Theologides, B. J. Kennedy, D. R. Kelly, S. L. Ewing, G. J. Vosika

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincrisine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in th CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in theCA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compard to two definite and three probable drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival bnefit.

Original language	English (US)
Pages (from-to)	997-1000
Number of pages	4
Journal	Cancer Treatment Reports
Volume	64
Issue number	8-9
State	Published - 1980

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Find It

Find It at U of M Libraries

Cite this

@article{f2b0f4e1b3a745f090c0d219c6bf51f6,

title = "Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine",

abstract = "Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincrisine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in th CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in theCA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compard to two definite and three probable drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival bnefit.",

author = "Vogelzang, {N. J.} and Trowbridge, {R. C.} and Frenning, {D. H.} and A. Theologides and Kennedy, {B. J.} and Kelly, {D. R.} and Ewing, {S. L.} and Vosika, {G. J.}",

year = "1980",

language = "English (US)",

volume = "64",

pages = "997--1000",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "8-9",

}

TY - JOUR

T1 - Chemotherapy for small cell bronchogenic carcinoma

T2 - CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine

AU - Vogelzang, N. J.

AU - Trowbridge, R. C.

AU - Frenning, D. H.

AU - Theologides, A.

AU - Kennedy, B. J.

AU - Kelly, D. R.

AU - Ewing, S. L.

AU - Vosika, G. J.

PY - 1980

Y1 - 1980

N2 - Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincrisine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in th CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in theCA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compard to two definite and three probable drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival bnefit.

AB - Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincrisine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in th CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in theCA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compard to two definite and three probable drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival bnefit.

UR - http://www.scopus.com/inward/record.url?scp=0019298620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019298620&partnerID=8YFLogxK

M3 - Article

C2 - 6256076

AN - SCOPUS:0019298620

SN - 0361-5960

VL - 64

SP - 997

EP - 1000

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 8-9

ER -

Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine

Abstract

UN SDGs

Find It

Other files and links

Fingerprint

Cite this